News

Groups urging need for revitalizing antimicrobial development call for passage of the bill this year  Today, five prominent national organizations — the Biotechnology Innovation Organization, the Cystic Fibrosis Foundation, the Infectious…

BIO’s Impact Ag & Environment Conference, Sept. 19-20, 2023, in Raleigh, N.C., is an opportunity for companies and non-governmental organizations working across agriculture, bioprocessing, and climate adaptation/mitigation to connect and…

BIO provided detailed comments to the Office of Management and Budget (OMB) regarding the Initial Proposals For Updating OMB’s Race and Ethnicity Statistical Standards.

BIO’s Chief Advocacy Officer Nick Shipley presents comments to the Committee as it considers reforms to encourage capital formation and investment opportunities for all Americans.

BIO has filed an amicus brief in U.S. ex rel. Scutte v. SuperValu Inc., which addresses the issue of the intent requirement under the False Claims Act (FCA). Specifically, BIO urges the Court to uphold the view that a firm does not…

The Biotechnology Innovation Organization (BIO) today signed onto an amicus brief to challenge a District Court’s unprecedented ruling (related to a single drug known as mifepristone) that would create regulatory barriers and potentially upend FDA’s…